U.S. Army Captain Michael Kelvington, commander of the Battle company, 1-508 Parachute Infantry battalion, 4th Brigade Combat Team, 82nd Airborne Division, bows next to remains of Gulam Dostager, a member of Afghan Local Police who was killed in the blast of an Improvised Explosive Device (IED) during the joint Tor Janda (Black Flag in Pashtu) operation, in Zahri district of Kandahar province, southern Afghanistan May 25, 2012.  REUTERS/Shamil Zhumatov  (AFGHANISTAN - Tags: MILITARY CIVIL UNREST CONFLICT TPX IMAGES OF THE DAY)

Reuters Photojournalism

Our day's top images, in-depth photo essays and offbeat slices of life. See the best of Reuters photography.  See more | Photo caption 

Members of the U.S. Navy Blue Angels fly over the World Trade Center in lower Manhattan as part of the 25th annual Fleet Week celebration in New York, May 23, 2012.  REUTERS/Eduardo Munoz (UNITED STATES - Tags: MILITARY ANNIVERSARY TPX IMAGES OF THE DAY)

Fleet Week

The U.S. Navy takes Manhattan for a week.  Slideshow 

Photo

The SpaceX mission

A privately owned unmanned rocket blasts off on a mission to be the first commercial flight to the International Space Station.  Slideshow 

Drug resistant H1N1 no major change in virus: WHO

Related Topics

Related Video

Video

WHO probes new H1N1 strain

Tue, Nov 24 2009

1 of 4. National Councillor Doris Fiala receives a vaccination during a H1N1 swine flu virus vaccination session for members of the national parliament, during the winter parliament session in Bern, November 24, 2009.

Credit: Reuters/Michael Buholzer

GENEVA | Thu Nov 26, 2009 12:59pm EST

GENEVA (Reuters) - Tamiflu resistance in some H1N1 patients with badly weakened immune systems does not seem to reflect a major change in the virus' susceptibility to the frontline drug, the World Health Organization said on Thursday.

Nine people in Britain and the United States developed a Tamiflu-resistant form of swine flu while being treated in hospital mainly for blood cancers, said WHO flu expert Keiji Fukuda.

"We don't know the full answer. But it is more likely that we are not seeing a change, a major shift in the epidemiology or in the properties of these viruses with regard to oseltamivir resistance," he told a weekly news conference.

He said Tamiflu, known generically as oseltamivir and made by Switzerland's Roche, was effective when used correctly and early.

About 75 cases of oseltamivir-resistant viruses have been reported worldwide in recent months, mostly isolated cases which have arisen after preventive treatment with the drug, he said.

"Right now we do not see any evidence of a large impact in immuno-compromised people with milder forms and we do not see a large impact in HIV-infected populations," he said.

FLU TO CONTINUE FOR WEEKS

Swine flu is expected to infect more people in the northern hemisphere in the next weeks before there is a downturn, but is less prevalent in the southern hemisphere, Fukuda said.

"... it's still too early to say whether we are seeing peaking of activity in the northern hemisphere. Again, we see differences on a country by country basis," he said.

H1N1 has killed at least 6,770 people, according to the WHO. Most people suffer mild symptoms and recover without special treatment.

Some serious side effects have occurred after inoculation, but mostly "we have seen that the serious events are not related to the pandemic vaccine," Fukuda said.

In Canada, six people had severe allergic reactions after vaccination, but all recovered. Canadian provinces have stopped using a particular batch of GlaxoSmithKline Plc vaccine.

"As we understand, none of this vaccine was distributed outside Canada," Fukuda said. "All of the unused doses of vaccine have been put on hold, that is they are not being used at this point while investigations go on."

Related Quotes and News

Company
Price
Related News
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.